Advertisement
Research Article

Identification of Human S100A9 as a Novel Target for Treatment of Autoimmune Disease via Binding to Quinoline-3-Carboxamides

  • Per Björk,

    Affiliation: Active Biotech AB, Lund, Sweden

    X
  • Anders Björk,

    Affiliation: Active Biotech AB, Lund, Sweden

    X
  • Thomas Vogl,

    Affiliation: Institute of Immunology, University of Münster, Münster, Germany

    X
  • Martin Stenström,

    Affiliation: Immunology Group, Lund University, Lund, Sweden

    X
  • David Liberg,

    Affiliation: Active Biotech AB, Lund, Sweden

    X
  • Anders Olsson,

    Affiliation: Active Biotech AB, Lund, Sweden

    X
  • Johannes Roth,

    Affiliation: Institute of Immunology, University of Münster, Münster, Germany

    X
  • Fredrik Ivars,

    Affiliation: Immunology Group, Lund University, Lund, Sweden

    X
  • Tomas Leanderson mail

    To whom correspondence should be addressed. E-mail: tomas.leanderson@med.lu.se

    Affiliations: Active Biotech AB, Lund, Sweden, Immunology Group, Lund University, Lund, Sweden

    X
  • Published: April 28, 2009
  • DOI: 10.1371/journal.pbio.1000097

Media Coverage of this Article

Found additional news media or blog coverage for the article? Please let us know.